Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, mild/moderate 76% Improvement Relative Risk Mortality, severe 60% Favipiravir  Hartantri et al.  LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? Retrospective study in Indonesia (March - December 2020) Lower mortality with favipiravir (p=0.00047) Hartantri et al., The Lancet Regional .., Feb 2023 Favors favipiravir Favors control

Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia

Hartantri et al., The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2023.100167
Feb 2023  
  Source   PDF   All   Meta
Retrospective 689 hospitalized patients in Indonesia, showing lower mortality with favipiravir treatment.
Study covers remdesivir and favipiravir.
risk of death, 76.0% lower, HR 0.24, p < 0.001, adjusted per study, mild/moderate, multivariable, Cox proportional hazards, day 28.
risk of death, 60.0% lower, HR 0.40, p = 0.04, adjusted per study, severe, multivariable, Cox proportional hazards, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hartantri et al., 9 Feb 2023, retrospective, Indonesia, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 December, 2020. Contact:
This PaperFavipiravirAll
Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia
Yovita Hartantri, Josephine Debora, Leonardus Widyatmoko, Gezy Giwangkancana, Hendarsyah Suryadinata, Evan Susandi, Elisabeth Hutajulu, Assica Permata Amalya Hakiman, Yesy Pusparini, Bachti Alisjahbana
The Lancet Regional Health - Southeast Asia, doi:10.1016/j.lansea.2023.100167
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Research in context Evidence before this study Before this study, we searched PubMed for articles that assessed factors associated with mortality in COVID-19 inpatients, using search terms ("COVID-19" OR "coronavirus") AND ("mortality" OR "death"), from March until April 2022. We found the mortality studies were mainly from China, America, and Europe that associated mortality with older age, male, and pre-existing comorbidities besides the severity of the disease itself. Indonesia had the second-highest total number of cases and deaths in South-East Asia. However, there were still limited studies and inadequate reliable data about COVID-19 mortality in Indonesia. Previously published studies in Indonesia reported a CFR of around 9.4% to 18%, associated with older age, male, pre-existing comorbidity, immediate ICU admission, and intubation. Laboratory parameters such as NLR, D-dimer, and lymphocyte count were also associated with a greater risk of overall mortality. Added value of this study This study is a retrospective cohort study of hospitalized COVID-19 patients in a top referral hospital in Bandung of West Java, the largest province in Indonesia, during the first ten months of the epidemic. Our report is the most comprehensive mortality study in our region that analyzed the clinical characteristics, laboratory parameters, and treatments associated with survival outcomes. The case fatality rate of 14.9% was similar to previous..
Alene, Yismaw, Assemie, Magnitude of asymptomatic COVID-19 cases throughout the course of infection: A systematic review and meta-analysis, PloS one
Altonen, Arreglado, Leroux, Murray-Ramcharan, Engdahl, Characteristics, comorbidities and survival analysis of young adults hospitalized with COVID-19 in New York City, PloS one
Azwar, Setiati, Rizka, Fitriana, Saldi et al., Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital, Acta Medica Indonesiana
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of COVID-19-Final Report, N Engl J Med
Benfield, Bodilsen, Brieghel, Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study, Clinical Infectious Diseases
Biswas, Rahaman, Biswas, Haque, Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and metaanalysis, Intervirology
Chedid, Waked, Haddad, Chetata, Saliba et al., Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy, Journal of infection and public health
Cox, Loman, Bogaert, Grady, Co-infections: potentially lethal and unexplored in COVID-19, The Lancet Microbe
Diabetes, Diagnosis and classification of diabetes mellitus, Diabetes care
Fan, Lu, Li, Ding, Wang, ACE2 expression in kidney and testis may cause kidney and testis infection in COVID-19 patients, Frontiers in medicine
Group, Dexamethasone in hospitalized patients with COVID-19, New England Journal of Medicine
Hariyanto, Japar, Kwenandar, Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and metaanalysis, The American journal of emergency medicine
Hu, Han, Pei, Yin, Chen, Procalcitonin levels in COVID-19 patients, International journal of antimicrobial agents
Jalili, Payandemehr, Saghaei, Sari, Safikhani et al., Characteristics and mortality of hospitalized patients with COVID-19 in Iran: a National Retrospective Cohort Study, Annals of internal medicine
Levey, Eckardt, Tsukamoto, Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney international
Lippi, Plebani, Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis, Clinica chimica acta; international journal of clinical chemistry
Lu, Yu, Liu, Survival analysis and risk factors in COVID-19 patients, Disaster Medicine and Public Health Preparedness
Opal, Girard, Ely, The immunopathogenesis of sepsis in elderly patients, Clinical infectious diseases
Pinte, Ceasovschih, Niculae, Antibiotic Prescription and In-Hospital Mortality in COVID-19: A Prospective Multicentre Cohort Study, Journal of Personalized Medicine
Rozaliyani, Savitri, Setianingrum, Factors Associated with Death in COVID-19 Patients in Jakarta, Indonesia: An Epidemiological Study, Acta Med Indones
Sahu, Cerny, Managing patients with hematological malignancies during COVID-19 pandemic
Salinas-Escudero, Carrillo-Vega, Granados-García, Martínez-Valverde, Toledano-Toledano et al., A survival analysis of COVID-19 in the Mexican population, BMC Public Health
Santoso, Sung, Hartantri, MDR Pathogens Organisms as Risk Factor of Mortality in Secondary Pulmonary Bacterial Infections Among COVID-19 Patients: Observational Studies in Two Referral Hospitals in West Java, Indonesia, International Journal of General Medicine
Shang, Wang, Zhang, The relationship between diabetes mellitus and COVID-19 prognosis: a retrospective cohort study in Wuhan, China, The American journal of medicine
Shinkai, Tsushima, Tanaka, Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infectious diseases and therapy
Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome, Clinical Research & Reviews
Surendra, Elyazar, Djaafara, Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study, The Lancet Regional Health-Western Pacific
Whelton, Williams, The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: More Similar Than Different, Jama
Wu, Wang, Kuo, An update on current therapeutic drugs treating COVID-19, Current pharmacology reports
Yang, Liu, -P, Tao, -Q et al., The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients, International immunopharmacology
Zhang, Wang, Jia, Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China, Clinical microbiology and infection
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop